Jazz Pharmaceuticals (NASDAQ:JAZZ) Given a $213.00 Price Target by Piper Jaffray Companies Analysts

Share on StockTwits

Piper Jaffray Companies set a $213.00 price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Friday, October 19th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Citigroup lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a buy rating in a research note on Tuesday, July 10th. Leerink Swann lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an outperform rating in a research note on Friday, August 17th. Evercore ISI reiterated a buy rating on shares of Jazz Pharmaceuticals in a research note on Friday, July 13th. B. Riley lifted their price target on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the stock a buy rating in a research note on Tuesday, June 26th. Finally, Seaport Global Securities reiterated a buy rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 9th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $191.94.

JAZZ stock traded up $3.38 on Friday, hitting $145.57. The company had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. Jazz Pharmaceuticals has a 12-month low of $130.15 and a 12-month high of $184.00. The company has a current ratio of 4.29, a quick ratio of 3.62 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $8.47 billion, a P/E ratio of 15.23, a P/E/G ratio of 0.76 and a beta of 1.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.32 by $0.26. The company had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the company posted $3.22 earnings per share. As a group, equities analysts predict that Jazz Pharmaceuticals will post 11.71 earnings per share for the current year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the sale, the chief executive officer now directly owns 281,215 shares in the company, valued at approximately $46,220,497.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction on Monday, October 15th. The shares were sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the sale, the chief financial officer now owns 32,768 shares in the company, valued at $5,179,965.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,730 shares of company stock worth $2,796,532. 3.90% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. Stratos Wealth Partners LTD. bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $106,000. Tiverton Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $198,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $204,000. Financial Gravity Wealth Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $192,000. Finally, FDx Advisors Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $244,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: Ex-Dividend

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.